Clare Bradley (2002)
DAFNE: author's response to electronic letters from 5th October to 22nd October 2002.
Full text access: Open
The rapid responses received following the publication of the DAFNE trial reflect the controversy surrounding the current inadequate management of Type 1 diabetes.  While it is true that the approach is not novel (Ullman, 5th Oct; Black,6th Oct; Reed, 9th Oct; Chaufan, 12th October, Cohen, 22nd Oct), it is new to the UK. The biomedical benefits of this intensified approach had been known for some time in parts of Europe [2,3] but is was unclear whether these could be transferred to a British health care setting. furthermore, the impact on quality of life was unknown, as psychological outcomes were not measured in the early German work.
This is a Published version
This version's date is:
is not peer reviewed
Deposited by () on
in Royal Holloway Research Online.Last modified on 12-May-2010